Abstract #0286

Assessment of Anti-Angiogenic Treatment in Glioblastoma Using Arterial Spin-Labeling and Dynamic Susceptibility Contrast Perfusion MRI in a Phase II Trial

Mei-Yun Wang¹, Wei-Ting Zhang¹, Poe-zhou chen¹, Thomas Benner¹, Divya S. Bolar¹, Tracy T. Batchelor², Rakesh K. Jain³, A. Gregory Sorensen¹

¹Radiology, Massachusetts General Hospital, Boston, MA, USA; ²Neurology, Massachusetts General Hospital, Boston, MA, USA; ³Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

Angiogenesis is an essential step in the growth and spread of solid tumor, and advances in MRI now permit detection of the hemodynamic changes of glioblastoma after treatment. In the current study, arterial spin-labeling (ASL) and first-pass dynamic susceptibility contrast (DSC) perfusion MRI were used to assess the treatment effect of an anti-angiogenic agent AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, in a phase-II clinical trial. Our results suggest ASL is almost as sensitive as DSC in assessing rCBF changes of tumor and the tumor vascular normalization and reversal after anti-angiogenesis treatment.